Nasdaq:US$16.90 (-0.82) | HKEX:HK$27.20 (-0.95) | AIM:£2.52 (-0.11)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors